ARROW points the way for RET fusion-positive NSCLC treatment

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Dec 22 / Springer Healthcare

ARROW points the way for RET fusion-positive NSCLC treatment

Oncology Non-Small Cell Lung Cancer

Description

Stephen Liu outlines the ARROW study design and findings and discusses the impact of pralsetinib on the care of patients with treatment-naïve and previously treated NSCLC positive for a RET fusion.

©Springer Healthcare 2021. This content has been independently developed by Springer Healthcare and licensed by Roche for Medically. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not reflect the views of Springer Healthcare. Springer Healthcare assumes no responsibility for any injury or damage to persons or property arising out of, or related to, any use of the material or to any errors or omissions. Please consult the latest prescribing information from the manufacturer for any products mentioned in this material.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.